Cubist Systematic Strategies’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Cubist Systematic Strategies’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19,000	Closed	-$55K	–	3891
2021 Q4	$55K	Sell	19,000 -17,125	-47%	-$63.3K	﹤0.01%	3305
2021 Q3	$153K	Sell	36,125 -35,672	-50%	-$159K	﹤0.01%	2651
2021 Q2	$380K	Buy	71,797 +57,396	+399%	+$276K	﹤0.01%	2183
2021 Q1	$67K	Buy	+14,401	New	+$65.3K	﹤0.01%	2706
2020 Q1	–	Sell	-28,719	Closed	-$173K	–	2551
2019 Q4	$173K	Buy	28,719 +17,615	+159%	+$120K	﹤0.01%	2072
2019 Q3	$84K	Buy	+11,104	New	+$125K	﹤0.01%	1970

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cubist Systematic Strategies's ZYNE Position: Q1 2022 in Review

Cubist Systematic Strategies sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2022, closing a stake of 19,000 shares — an estimated $55K sold.

Cubist Systematic Strategies first reported a position in ZYNE in Q3 2019 and held it in 6 quarters. The position peaked at $380K in Q2 2021. 59 funds tracked by Wall St. Rank hold ZYNE as of Q1 2022.

Cubist Systematic Strategies reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
Cubist Systematic Strategies sold 19,000 Zynerba Pharmaceuticals, Inc shares in Q1 2022, an estimated $55K.
Cubist Systematic Strategies first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2019 and held it in 6 quarters.
Cubist Systematic Strategies's Zynerba Pharmaceuticals, Inc position peaked at $380K in Q2 2021.
59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2022.

Based on Cubist Systematic Strategies's 13F filing for Q1 2022, filed 16 May 2022.